Ranbaxy Enhances Facility Operations But Deadlock On FDA Action Remains
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Daiichi Sankyo's India affiliate Ranbaxy has put in place enhanced systems and processes to upgrade its manufacturing facilities and R&D centers to respond to U.S. FDA punitive actions related to alleged lapses in good manufacturing practices at Ranbaxy's two India-based sites
You may also be interested in...
Daiichi Sankyo Buys Its First U.S. Packaging and Manufacturing Plant
Daiichi Sankyo Inc. has purchased a plant in Bethlehem Township, Pa., that will package the seven products the company currently markets in the U.S. The facility may also eventually manufacture Daiichi products
Daiichi Sankyo Buys Its First U.S. Packaging and Manufacturing Plant
Daiichi Sankyo Inc. has purchased a plant in Bethlehem Township, Pa., that will package the seven products the company currently markets in the U.S. The facility may also eventually manufacture Daiichi products
Daiichi Sankyo Buys Its First U.S. Packaging and Manufacturing Plant
Daiichi Sankyo Inc. has purchased a plant in Bethlehem Township, Pa., that will package the seven products the company currently markets in the U.S. The facility may also eventually manufacture Daiichi products.